Notes from Terry Kungel former Chair of MCFPC:
At the Brunswick area Support group meeting there was a conversation about Androgen Receptor Splice Variant 7 status. Terry made the point that the work he and Stu Hunter did together makes a compelling case for men to be tested for the AR-V7 status before starting Xtandi or Zytiga and they should also definitely be tested for their AR-V7 status if their PSA levels begins to increase during the time they are taking these drugs.
Men who are AR-V7 negative can see positive control of their prostate cancer progress for 2-3 years. AR-V7 status can migrate to positive and at this point neither Xtandi or Zytiga will produce any benefit. The mechanism for the change from negative to positive is still under study.